

**Hadrontherapy
and
EU clinical networks:
status and perspectives**

Lisa Licitra & Ester Orlandi





European Reference Networks

EpiCARE . BOND
 . CRANIO . ENDO .
 ERKNet . EYE . ERNICA .
 VASCERN . LUNG . RND . SKIN
 . EURACAN . GUARD-HEART
 . EuroBloodNet . eUROGEN .
 GENTURIS . ITHACA . MetabERN
 . PaedCan . RARE-LIVER .
 ReCONNET . EURO-NMD .
 TRANSPLANT-CHILD .
 RITA

Share. Care. Cure.



EuroBloodNet

EURACAN



European Reference Network
for rare or low prevalence complex diseases


Network
Paediatric Cancer
(ERN PaedCan)



European Reference Network
for rare or low prevalence complex diseases

Network
Genetic Tumour Risk
Syndromes (ERN GENTURIS)

GOVERNANCE






- promote good quality and safe **care** to patients by fostering proper diagnosis, treatment, follow-up and management of patients across the Network
- empower and involve **patients**
- offer and promote **multi-disciplinary advice for complex cases**
- develop and implement **clinical guidelines** and cross-border patient pathways
- exchange, gather and **disseminate knowledge** evidence and expertise within and outside the Network
- promote collaborative **research** within the Network
- reinforce research and **epidemiological surveillance**, through setting up of shared registries
- exchange and disseminate knowledge and best practices, in particular by supporting **national centres and networks**




1. Head & neck cancers
2. Sarcomas
3. Digestive rare cancers
4. Neuroendocrine tumours
5. Rare thoracic cancers
6. Endocrine gland tumours
7. Central nervous system tumours
8. Rare female genital cancers
9. Rare urological and male genital tumours
10. Rare skin cancers & non-cutaneous melanoma

Registry Model



Performing an analysis across multiple decentralized data sources, without exchanging their data.





Brussels, 3.2.2021
COM(2021) 44 final

**COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN
PARLIAMENT AND THE COUNCIL**

Europe's Beating Cancer Plan

{SWD(2021) 13 final}



(a) Preparatory activities to establish **National Comprehensive Cancer Centres** and EU Network linking these Centres:

The aim of this **joint action** is to establish or upgrade Comprehensive Cancer Centres in Member States, and the creation of an EU network of the already existing and newly established Comprehensive Cancer Centres.

The EU **Network** of National Comprehensive Cancer Centres will support the **implementation** of quality-assured early detection, screening, diagnosis, **treatment**, support to cancer survivors, and training of the cancer workforce.



(b) Preparatory activities to establish an **EU Network of Expertise on Cancers** and Cancer Conditions:

The aim of this joint action is to establish the new EU Network of Expertise on Cancers and Cancer Conditions.

The EU Network will link with the existing four European Reference Networks for Rare Cancers and a group of new (possibly 5) EU Networks of Expertise to be funded under this action. This action will prepare the establishment of new EU Networks of Expertise, which will be supported to target specific, challenging cancer conditions, benefiting from cross-border cooperation and Union expertise. These conditions include **metastatic diseases**, **co-morbidities** in cancer care, **complex cancers with poor prognosis** and specific conditions related to **genomics in cancer care**, **integrative oncology**, **palliative care** and **survivorship**.



poor-prognosis cancers

personalized prevention

survivorship

palliative care

adolescents young adults

omic technologies

high-tech resources






- innovative radiotherapies
- nuclear medicine
- radiomics
- innovative surgery
- ablations
- cell therapies
- ex-vivo testing








Focus of NoEs...

- **Guidelines/recommendations**
- **Advocacy/policy/awareness**
- **Healthcare organizational models**
- **Education (professionals, patients)**
- **Research promotion**
- **Quality criteria**
- **Patient and public engagement**

.....






NoE



- **ERNs' model in rare cancers**
- **Sustainability**
- **Integration between healthcare & research**
- **Integration between EU networking & MSs**
- **Integration between IT tools and EHR (incl. AI tools)**
- **Patient involvement**



MEMBER STATES REPRESENTATION IN THE NoE

| 21 countries involved | Domain | | | | | | | TOTAL |
|-----------------------|------------------|-----------|---------------------------|--------------------|------------------------------|----------------|---------------------------|-------|
| | Nuclear medicine | Radiomics | Innovative radiotherapies | Innovative surgery | Physical methods of ablation | Cell therapies | Ex-vivo testing of agents | |
| Belgium | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 13 |
| Bulgaria | | | | | | | | 0 |
| Denmark | 1 | | 1 | 1 | 1 | 1 | 1 | 6 |
| Estonia | | | 1 | | | | | 1 |
| France | 1 | 2 | 3 | 1 | 2 | 2 | 1 | 12 |
| Greece | | 1 | 1 | | 1 | 1 | 1 | 5 |
| Hungary | | | | 1 | | 1 | | 2 |
| Italy | | 3 | 2 | 2 | 1 | 3 | | 11 |
| Latvia | | | 1 | | 2 | 2 | 1 | 6 |
| Lithuania | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 10 |
| Luxembourg | 3 | | 2 | | 3 | 2 | 3 | 13 |
| Moldova | | | 1 | | | | | 1 |
| Netherlands | 1 | | | | | | | 1 |
| Norway | 1 | 1 | 1 | 1 | | 1 | | 5 |
| Poland | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 12 |
| Portugal | | | | | | 1 | 1 | 2 |
| Romania | | 2 | 1 | | 1 | | | 4 |
| Slovenia | 1 | | | 1 | 2 | 2 | 1 | 7 |
| Spain | 1 | 1 | 3 | 2 | | 4 | 1 | 12 |
| Sweden | | | 1 | | 1 | 2 | | 4 |
| Ukraine | | | | 1 | | | | 1 |
| Croatia | | | | | | | | 0 |
| Cyprus | | | | | | | | 0 |
| Czech Republic | | | | | | | | 0 |
| Germany | | | | | | | | 0 |
| Iceland | | | | | | | | 0 |
| Ireland | | | | | | | | 0 |
| Malta | | | | | | | | 0 |
| TOTAL | 13 | 14 | 23 | 14 | 18 | 29 | 17 | |

Call: EU4H-2023-JA-3-IBA

(Joint Actions third wave)

Topic: EU4H-2023-JA-3-IBA-08

Type of Action: EU4H-PJG

(EU4H Project Grants)

Proposal number: 101183265

Proposal acronym: JANE-2

Type of Model Grant Agreement: EU4H Action Grant Budget-Based

Coordination from Istituto Nazionale Tumori in Milan, Italy

The impact of this JA will stem from the impact of the NoEs which it will give rise to. That said, their effectiveness will be mostly dictated by how far the new kind of EU health networking can overcome some of the challenges currently being experienced. This is why this project is equipped to assess such problems and work out possible solutions. The ambition here is to root these solutions in the European oncology community as deeply as possible. Indeed, the idea behind the concept of JAs is to involve communities of stakeholders, together with MSs and EU bodies, as widely as possible. We understand that if the launching of new NoEs was not envisaged merely as an administrative endeavour, and a dedicated JA was conceived, the reason is exactly to tackle some problems of EU health care networking by addressing them through a wide involvement of the European oncology community. Thus, the ambition of this JA is actually to be able to involve the whole European oncology community pragmatically, i.e. in an attempt to bring about the creation of a new kind of network, as anticipated by the Commission, capable of being effective, appropriate, and sustainable.

The ambition of the new NoEs, as far as their mandates are concerned, will obviously be to bring the added value of EU networking to some crucial oncology areas. Health care networking can be exceedingly important in Europe, since it gives the EU the potential to target its citizens in a coordinated fashion. In a sense, Europe is privileged by being able to exploit health care networking to an extent which is not accessible to most other areas of the world. In fact, the EU has the unique opportunity to drive healthcare providers in so many countries to collaborate with each other on a networking basis, provided that they operate in an environment which, although different from country to country, is reasonably homogenous, with special regard to the universal access to health care which it allows. Thus, healthcare networking is an organizational solution which seems very distinctive to Europe, and the EU can really exert a specific added value. All the more, since the expected outcome may be tremendous, it is vital to address all problems and obstacles. By launching JAs on healthcare networking, complementing the current networking in the rare cancer area through existing ERNs, the EU is sending a clear signal to its citizens and to the health systems of its MSs. This JA has the ambition to take on the challenge, within the scope of the NoEs to which it will give rise.

- Eu healthcare networking
- Challenges/solutions
- Wide involvement of the EU oncological community
- Eu as driving force for an universal access to care

Work Package 10: NoE on Hi-tech medical resources

| | | | |
|------------------|----------|--------------------------|--|
| Duration: | M1 – M48 | Lead Beneficiary: | Lead FR-Unicancer Co-lead DA - Region Zealand - Zealand University Hospital |
|------------------|----------|--------------------------|--|

Objectives

The NoE on Hi-tech medical resources focuses on technologies that work across all cancers and are highly specialised and innovative. This network aims at finding solutions allowing patients across the EU to benefit from increased knowledge and expertise and more accessible health services. As emerging resources tend to be expensive and rare, particular attention will be paid to their equal access for EU citizens.

This network contains 7 domains:

- 1. Nuclear Medicine.** This modality is well established across Europe in cancer centres. However, current developments with novel tracers reveal hitherto unseen possibilities for precise diagnostics and consequently treatment.
Lead / co-lead: Unicancer (FR) - CLB & CHB; CSGV (SP)
Participants: IJB-ULB (BE); REGIONH (DK), SAM (LT), INC (LU), HRS (LU), CHL (LU), OUS (NO), MSCl (PL), UKCL (SL); KU Leuven (BE); Mater Misericordiae University Hospital (IE)
- 2. Radiomics.** This novel discipline allows an extension of imaging not only to describe disease morphology, but also to decipher information about cancer biology.
Lead / co-lead: Unicancer (FR) – IUCT; NKUA (GR)
Participants: IJB (BE), FHF (FR), IRCC AOUBO (IT), LSMUL KK (LT), IOCN (RO), CSGV (SP); UGent (BE), CRO-Aviano (IT), IRCCS ISNB (IT), OUS (NO), MSCl (PL)
- 3. Innovative radiotherapy.** Radiotherapy is a cornerstone of cancer therapy. Novel, innovative and highly specialized techniques such as hadron therapy allow new advances in treatment efficacy.
Lead / co-lead: CNAO (IT); Unicancer (FR) - CLB
Participants: IJB-ULB (BE), USHATO (BU) NHRF (GR), PSCUH (LV), LSMUL KK (LT); RM (DK), PERH (ES), FHF (FR), CRO-Aviano (IT), CFB (LU), INC (LU), PMSI IO (MO), OUS (NO), MSCl (PL), IOCN (RO), IDIVAL (SP), SoS (SW), CSGV (SP); KU Leuven (BE), INCa (FR), HSJD (SP), St Lukes Radiation Oncology Ntwk (IE)
- 4. Innovative surgery.** Novel surgical approaches are being developed, and integration with e.g. machine learning based decision support system or imaging-guided robotics, allows improved patient outcomes.
Lead / co-lead: Ol Ljubljana (SL); OUS (NO)
Participants: UNICANCER (FR), IOV(IT), CSGV(SP); UGent (BE), ZEALCO (DK), OOI (HU), IOV(IT), LSMUL KK (LT), VULSK (LT), CHL (LU), MSCl (PL), UKCL (SL), NCI (UKR); HSDJ (SP); MMUH (IE)
- 5. Physical methods of ablation.** Ultrasounds, radiofrequency, electroporation, etc. Their rapid development and increasing use for oligometastatic disease allows more treatment options.
Lead / co-lead: ZEALCO (DK); OIL(SL)

Participants: UNICANCER (FR), IRCCS AOUBO (IT), VGR (SW); UGent (BE), NKUA (GR), REUH (LV), SAM (LT), VULSK (LT), HRS (LU), CHL (LU), INC (LU), MSCl (PL), IOCN (RO), UKCL (SL); INCa (FR); St Vincent's University Hospital (IE)

6. **Cell therapies.** Cell therapies encompass the use of immune cells from patients and donors to treat cancer and are gaining increasing relevance in cancer treatment. Cell therapies are highly specialized and require extensive lab facilities.

Lead / co-lead: Unicancer (FR) – IPC; IRST (IT)

Participants: IRCCS AOUBO (IT), PSCUH (LV), LU (LV), LSMUL KK (LT), IBB PAN (PL), MUL (PL), MUW (PL), AUH (SW), CSGVA (SP); REGIONH (DK), NKUA (GR), INC (LU), LIH (LU), OUS (NO), MSCl (PL), IPOP (PT), UKCL (SL), HSJD (SP), IDIVAL (SP), UPPSALA (SW); KU Leuven (BE), INCa (FR), OOI (HU); Galway University Hospital & St James' Hospital (IE)

7. **Ex-vivo testing of agents.** Techniques involving patient-derived cell cultures as a platform to investigate cancer drugs efficacy in specific patients. The setup requires expertise and extensive lab facilities to grow samples from a larger number of patients.

Lead / co-lead: Unicancer (FR) - Curie Institute; NHRF (GR)

Participants: LU (LV), LSMUL KK (LT), IBB PAN (PL), MUW (PL), I3S (PT), CSGV (SP); UGent (BE), RSYD (DK), VULSK (LT), INC (LU), LNS (LU), LIH (LU), MSCl (PL), OI (SL); KU Leuven (BE)

These domains represent highly specialized and innovative technologies for which some challenges are common, thus, some tasks are set across all domains (T10.1, T10.2, T10.3). However, these technologies are also at different levels of maturity and possibilities for access across Europe, and needed infrastructure differs between them. Therefore, other tasks are domain-specific (10.4, 10.5, 10.6).

Specific objectives of the NoE (common to all domains) are the following:

- To organise of the governance of the network
- To establish recommendations for Member States regarding urgent needs and biggest gaps across Europe
- To position the network at the forefront of innovation

Specific objectives under the responsibility of each domain are:

- To support centres to better integrate innovative therapies
- To improve continuous medical education and enhancing patient and public literacy and involvement
- To ensure the visibility and the sustainability of the network through dissemination activities and evaluation criteria set-up
- To engage international and national scientific societies (e.g. ESMO, ESTRO) in these goals
- To identify and engage EU official bodies (EMA, EUnetHTA) in identifying obstacles to implementation and progress
- To address and collaborate with patient advocacy groups


| | | | | | | | |
|-------|--|----|-----------------------------|----------|-------------|-----|--|
| D10.1 | Recommendation paper for the future governance of the NoE on Hi-tech medical resources | 10 | UNICANCER (FR), ZEALCO (DK) | Document | PU - Public | M48 | Word document, English Recommendations on: <ul style="list-style-type: none"> - Future governance of the NOE; - Tackling inequalities; - Implementation and access; - Training; |
| D10.2 | Paper on emerging uses of hi-tech innovation in described domains and implications and strategies for access across Europe | 10 | Domain leaders & co-leaders | Document | PU - Public | M48 | Scientific journal manuscript (English) |
| D10.3 | Paper on information to patients | 10 | Domain leaders & co-leaders | Document | PU - Public | M48 | Scientific journal manuscript (English) |
| D10.4 | Paper on vision for development of hi-tech innovation in described domains | 10 | Domain leaders & co-leaders | Document | PU - Public | M48 | Scientific journal manuscript (English) |
| D10.5 | Policy paper on provision of access to hi-tech innovation in described domains | 10 | Domain leaders & co-leaders | Document | PU - Public | M48 | Scientific journal manuscript (English) |

High tech medical innovation

1. Nuclear Medicine



2. Radiomics



3. Innovative Radiotherapies




4. Innovative Surgery



5. Physical Methods of Ablation



6. Cell Therapies



7. Ex-vivo Testing of Agents



**TASK 1
Governance
of the NoE**

*Organizing the
governance
of the network*

Governance of
the network and
of the domains
(based on the
endorsement
criteria)

Synergies with
the other NoEs
of JANE

Collaborations &
funding
opportunities
(with scientific
societies, other
existing
stakeholders and
projects)

**TASK 2
Advocacy**

*Establishing
recommendations for
Member States
regarding urgent
needs and biggest
gaps across Europe*

Mapping inequalities
in Europe (resources
/medicine access,
reimbursement,
funding, HCP shortages
/ skills, public
information)

Addressing
challenges in
healthcare inequity
to better implement
and access
innovative therapies
& highlighting
opportunities for
more efficient &
sustainable
healthcare systems

**TASK 3
Innovation
Observatory**

*Positioning the
network at the
forefront of
innovation*

Identifying new
therapies

Clinical
guidelines
elaboration in
collaboration
with relevant
stakeholders

Action plan of
how innovation
should be led
through
medicine

Identifying
challenges to
bench to
bedside
transition and
implementation

**TASK 4
Infrastructural
and procedural
support**

*Supporting centers
to better integrate
innovative
therapies*

Facilitate the
implementation of
CPGs into
standards of care

Helping less
advanced centers
/countries
(installing and
operating needs,
consequences on
the organization)

Speeding up the
road from
innovation to
patient benefit

**TASK 5
Education
& Training**

*Improving
continuous
education of
health care
professionals
and enhancing
patient and
public literacy
and
involvement*

Capacity
Building
activities

Online
webinars

Public
awareness
activities
(infodays on
new promising
resources)

*In collaboration
with patients
organisations
and the
EUnetworkCCC*

**TASK 6
Dissemination
& Sustainability**

*Ensuring the visibility
and the sustainability
of the network*

1 or 2 use cases to
showcase at the
end of the project

Dissemination
relevant
collaborators

Dissemination in
the EU Member
States

Partners
enlargement
(centers/experts)

1. Nuclear Medicine

2. Radiomics

**3. Innovative
radiotherapy**

**4. Innovative
surgery**

**5. Physical methods
of ablation**

6. Cell therapies

**7.Ex-vivo testing
of agents**

3. Innovative Radiotherapies



Joint Action **JANE** – GA 101075328



WP 10 NETWORK OF EXPERTISE ON HI-TECH MEDICAL RESOURCES

Lead: CNAO (Italy), Pr. Ester Orlandi – Chief of Clinical Department, National Center for Oncological Hadrontherapy
Co-lead: Centre Léon Bérard, Unicancer (France), Pr. Vincent Gregoire – Chair of the Radiation Oncology Department



INNOVATIVE RADIOTHERAPIES - DOMAIN 3 - PARTNERS

| Acronym | Organisation name | Country | CA/AE | Contact person | Email | Domain 3 Innovative radiotherapies |
|------------|---|---------|-------|----------------------------|--|------------------------------------|
| CUSL | Clinique universitaire Saint-Luc | Belgium | AE | Prof. Jean-Pascal Machiels | jean-pascal.machiels@saintluc.uclouvain.be | OBSERVER |
| CUSL | Clinique universitaire Saint-Luc | Belgium | AE | Guillaume Dachy | guillaume.dachy@saintluc.uclouvain.be | OBSERVER |
| IJB-ULB | Institut Jules Bordet | Belgium | AE | Dirk Vangestel | dirk.vangestel@hubruxelles.be | HIGH |
| IJB-ULB | Institut Jules Bordet | Belgium | AE | Jonathan Cimino | jonathan.cimino@hubruxelles.be | HIGH |
| KU Leuven | KU Leuven | Belgium | AE | Evy Lobbestael | evy.lobbestael@kuleuven.be | OBSERVER |
| KU Leuven | KU Leuven | Belgium | AE | Johan Van Lint | johan.vanlint@kuleuven.be | OBSERVER |
| RM | Central Denmark Region - Aarhus University Hospital, Danish Center for Particle Therapy | Denmark | AE | Cai Grau | cai.grau@rm.dk | LOW |
| ZEALCO | Region Zealand - Zealand University Hospital - Dept. of Clinical Oncology and Palliative Care | Denmark | CA | Keld Hundewadt | kehun@regionsjaelland.dk | LOW |
| PERH | Põhja-Eesti Regionaalhaigla | Estonia | AE | Kätlin Tiigi | katlin.tiigi@regionaalhaigla.ee | LOW |
| FHF | Fédération Hospitalière Française | France | AE | Vincent Bourbonne | vincent.bourbonne@chu-brest.fr | LOW |
| FHF | Fédération Hospitalière Française | France | AE | Vincent Ollivier | v.ollivier@fhf.fr | LOW |
| INCa | Institut National du Cancer | France | CA | Caroline Le Dour | clédour@institutcancer.fr | OBSERVER |
| INCa | Institut National du Cancer | France | CA | Margaux Le Gall | MLEGALL@institutcancer.fr | OBSERVER |
| Unicancer | Unicancer - Centre Oscar Lambret (Lille) | France | AE | David Pasquier | d-pasquier@o-lambret.fr | LOW |
| Unicancer | Unicancer - Centre Oscar Lambret (Lille) | France | AE | Eric Lartigau | e-lartigau@o-lambret.fr | LOW |
| Unicancer | Unicancer - Institut Gustave Roussy (Paris) | France | AE | Eric Deutsch | eric.deutsch@gustaveroussy.fr | LOW |
| Unicancer | Unicancer - Centre Léon Bérard (Lyon) | France | AE | Vincent Grégoire | Vincent.GREGOIRE@lyon.unicancer.fr | Co-LEADER |
| NHRF | ETHNIKO IDRYMA EREVNON | Greece | CA | Dr Alexandros Pintzas | apint@eie.gr | HIGH |
| NHRF | ETHNIKO IDRYMA EREVNON | Greece | CA | Dr Theodora Katsila | thkatsila@eie.gr | HIGH |
| NHRF | ETHNIKO IDRYMA EREVNON | Greece | CA | Dr Dimitra Mitsiou | dmitsiou@eie.gr | HIGH |
| NHRF | ETHNIKO IDRYMA EREVNON | Greece | CA | Dr Christos Chochos | chochos@eie.gr | HIGH |
| CNAO | Centro Nazionale di Adroterapia Oncologica | Italy | AE | Ester Orlandi | ester.orlandi@cnao.it | LEADER |
| CNAO | Centro Nazionale di Adroterapia Oncologica | Italy | AE | Tiziana Golme | tiziana.golme@cnao.it | LEADER |
| CNAO | Centro Nazionale di Adroterapia Oncologica | Italy | AE | Lisa Licitra | lisa.licitra@istitutotumori.mi.it | LEADER |
| CNAO | Centro Nazionale di Adroterapia Oncologica | Italy | AE | Chiara Marazzi | chiara.marazzi@cnao.it | LEADER |
| CRO-Aviano | CRO Aviano IRCCS | Italy | AE | Maurizio Mascarin | mascarin@cro.it | LOW |
| CRO-Aviano | CRO Aviano IRCCS | Italy | AE | Lorenzo Vinante | lorenzo.vinante@cro.it | LOW |
| CRO-Aviano | CRO Aviano IRCCS | Italy | AE | Andrea Dassie | andrea.dassie@cro.it | LOW |
| CRO-Aviano | CRO Aviano IRCCS | Italy | AE | Paolo Chiovati | pchiovati@cro.it | LOW |
| CRO-Aviano | CRO Aviano IRCCS | Italy | AE | Michele Avanzo | mavanzo@cro.it | LOW |
| PSCUH | Pauls Stradins Clinical University Hospital | Latvia | CA | Reičela Heinrihsone | reicela.heinrihsone@stradini.lv | HIGH |
| PSCUH | Pauls Stradins Clinical University Hospital | Latvia | CA | Aija Geriņa-Bērziņa | aija.gerina-berzina@stradini.lv | HIGH |

INNOVATIVE RADIOTHERAPIES - DOMAIN 3 - PARTNERS



| | | | | | | |
|-------------|---|------------|----|-----------------------------------|--|----------|
| LSMUL KK | Hospital of Lithuanian University of Health Sciences Kauno klinikos | Lithuania | AE | Assoc. Prof. Sigita Liutkauskienė | sigita.liutkauskiene@kaunoklinikos.lt | LOW |
| LSMUL KK | Hospital of Lithuanian University of Health Sciences Kauno klinikos | Lithuania | AE | Gailė Vencloviėnė | gailė.vencloviene@kaunoklinikos.lt | LOW |
| LSMUL KK | Hospital of Lithuanian University of Health Sciences Kauno klinikos | Lithuania | AE | Viktoras Rudzianskas | viktoras.rudzianskas@kaunoklinikos.lt | LOW |
| LSMUL KK | Hospital of Lithuanian University of Health Sciences Kauno klinikos | Lithuania | AE | Laimonas Jarusevicius | laimonas.jarusevicius@kaunoklinikos.lt | LOW |
| LSMUL KK | Hospital of Lithuanian University of Health Sciences Kauno klinikos | Lithuania | AE | Erika Korobeinikova | erika.korobeinikova@kaunoklinikos.lt | LOW |
| CFB | Centre François Baclesse | Luxembourg | AE | Prof. Guillaume Vogin | guillaume.vogin@baclesse.lu | LOW |
| INC | Institut National du Cancer | Luxembourg | CA | Dr Nikolai Goncharenko | nikolai.goncharenko@inc.lu | LOW |
| INC | Institut National du Cancer | Luxembourg | CA | Dr Amélie Gaignaux | Amelie.Gaignaux@inc.lu | LOW |
| PMSI IO | PMSI Institute of Oncology | Moldova | CA | Horia Vulpe | horiavulpe@gmail.com | LOW |
| PMSI IO | PMSI Institute of Oncology | Moldova | CA | Minzatean Artiom | tiomat9@gmail.com | LOW |
| OUS | Oslo University Hospital, Department of Oncology | Norway | CA | Per Magnus | PEMM@ous-hf.no | x |
| OUS | Oslo University Hospital, Department of Oncology | Norway | CA | Jan Rødal | jro@ous-hf.no | LOW |
| OUS | Oslo University Hospital, Department of Oncology | Norway | CA | Marianne G. Guren | Marianne.Gronlie.Guren@ous-hf.no | LOW |
| MSCI | M. Skłodowska-Curie National Research Institute of Oncology - National Research Ins | Poland | CA | Tomasz Rutkowski | Tomasz.rutkowski@gliwice.nio.gov.pl | LOW |
| MSCI | M. Skłodowska-Curie National Research Institute of Oncology - National Research Ins | Poland | CA | Slwomir Blamek | Slawomir.blamek@gliwice.nio.gov.pl | LOW |
| IOCN | INSTITUTUL ONCOLOGIC PROF DR ION CHIRICUTA CLUJ-NAPOCA (IOCN) | Romania | CA | Andrei Roman | andrei.roman678@gmail.com | LOW |
| IOCN | The Oncology Institute, Cluj-Napoca | Romania | AE | Delia Nicoara | delianicoara13@gmail.com | LOW |
| CSGVA | Conselleria de Sanitat, Generalitat Valenciana | Spain | AE | Mariola Penadés Fons | penades_marfon@gva.es | HIGH |
| FSJD | Fundació Privada per a la Recerca i la Docència Sant Joan de Déu | Spain | AE | Andrés Morales La Madrid | andres.morales@sjd.es | OBSERVER |
| HUMV-IDIVAL | Fundación Instituto de Investigación Marqués de Valdecilla | Spain | AE | Fernando Rivera Herrero | fernando.rivera@scsalud.es | LOW |
| HUMV-IDIVAL | Fundación Instituto de Investigación Marqués de Valdecilla | Spain | AE | Ignacio José Durán Martínez | ignaciojose.duran@scsalud.es | LOW |
| HUMV-IDIVAL | Fundación Instituto de Investigación Marqués de Valdecilla | Spain | AE | Carlos López López | carlos.lopez@scsalud.es | LOW |
| HUMV-IDIVAL | Fundación Instituto de Investigación Marqués de Valdecilla | Spain | AE | Itziar Gardeazábal González | itziar.gardeazabal@scsalud.es | LOW |
| HUMV-IDIVAL | Fundación Instituto de Investigación Marqués de Valdecilla | Spain | AE | Fernanda Genre Romero | fgenre@idival.org | LOW |
| SoS | National Board of Health and Welfare (Socialstyrelsen) | Sweden | AE | Hillevi Rylander | Hillevi.Rylander@skandion.se | LOW |
| NCI | National Cancer Institute | Ukraine | CA | Andrii Horodetskyi | andriy.gorodetskiy@unci.org.ua | LOW |

Which stakeholders should we contact to join the project for this domain?

- Existing projects/tools/networks
- Relevant scientific societies
- Relevant industrial partners
- Missing relevant stakeholders, including from missing Member States
- Existing training programs

- ❖ Existing projects/tools/networks: Hitriplus (<https://www.hitriplus.eu/>), PIANOFORTE (<https://pianoforte-partnership.eu/>)
- ❖ Relevant scientific societies/ industrial partners : any other suggestions?
[Link](#)
- ❖ Missing relevant stakeholders, including from missing Member States
A couple of considerations:

NoE's Missing Countries: Germany, Cyprus, Austria, Finland, Croatia
Among Domain 3 - WP10 MISSING there are: Slovenia, **Netherlands**, Moldova, Hungary, Ireland, **Portugal + Germany**, Cyprus, **Austria, Finland**, Croatia

How to involve them: Institutions? Clinical and Radiation Oncologist societies? Research group?

- ❖ Existing training programs: Hitriplus (<https://www.hitriplus.eu/>), Euracan, Phd program (UPLIFT) → Ideas?

How can we envision this domain within 4 years?

- Based on the milestones and deliverables planned for your domain, what are the priorities in order to start working together?
- How will you connect with the 6 other networks of expertise JANE 2 and with the EUnetCCC (CrANE follow-up)?

Task 4 – Infrastructural Infrastructural and procedural support

- **Milestone: Workshop on mapping Innovative Radiotherapy techniques and technologies, and country-based processes for implementation of innovative techniques**
- Milestone: Workshop on designing a roadmap for Innovative Radiotherapy involves addressing clinical and technical state-of-the-art scenarios to aid less advanced centers in the implementation of innovations
- Deliverable: Document on mapping Innovative Radiotherapy: exploring future roadmap agendas for Radiotherapy Innovation, methods, and implementation
- Deliverable: Document on establishing a Values-Based framework for comprehensive evaluation of innovations in Radiotherapy

Task 5 – Education and training

- Milestone: Developing a European platform for training exchanges and facilitating access to technical and clinical knowledge of Innovative radiotherapy
- Milestone: Creating a model to empower patients by providing a comprehensive overview of the available treatment options and technologies across Europe in close collaboration with patients associations
- Deliverable: Report on perspectives and training needs of clinical staff regarding Innovative Radiotherapy Resources
- Deliverable: Document on the role of patients associations in advancing Innovative Radiotherapy

Task 6 – Dissemination & Sustainability

- Milestone: Describing workflows for assessing patient needs in specific radiotherapeutic options and enhancing access
- Milestone: Implementing a model for patient empowerment to enhance patients' ability to make informed decisions about their healthcare, particularly regarding innovative radiotherapy
- Deliverable: Document on procedures for evaluating patient requirements in particular radiotherapy choices and improving accessibility to innovation
- Deliverable: Document on frameworks for patient empowerment

Mapping innovative radiotherapy techniques and technologies in Europe

European radiation oncology perspective on value-based innovation high tech radiotherapy


- 1. Radiotherapy (RT) innovation is highly focused on the precision and accuracy of radiation planning and delivery.
- 2. Value-based oncology aims to optimize patient outcomes while also considering the cost-effectiveness of treatments. In the context of radiotherapy, it encompasses a broad concept that has yet to achieve a definitive definition.
- 3. In the context of radiotherapy, defining core endpoints and a value scale must primarily consider:
 - I. Intervention types (e.g., stepwise versus incremental technological innovations);
 - II. Methods for testing clinical evidence and different timelines for testing;
 - III. Endpoint categorization (including survival-related endpoints, functional outcomes, acute and late toxicity and complications, as well as economic and operational endpoints such as resource use, costs, and quality).
- 4. Aim of the present [survey](#):
 - To map innovative RT techniques and technologies in Europe, as well as to gather the European radiation oncology perspective on value-based innovation in high-tech RT.

How will you connect with the 6 other NoEs of JANE 2 and with CraNE 2 (EUnetCCC)?

- WP 5: Complex cancer Case Study on lung or pancreas (TBD). Interesting connection to be made with T5.3 (Research & Innovation)
- WP 6: None
- WP7 : Survivoship Value-Based Model implementation
- WP8 : None
- WP 9 Omics: Traslational research on Radiation Terapies. Interest on task 9.2
- WP 10 (us): Important collaboration in task T10.3 & T10.2
- WP 11 AYA: Development and implementation on Value-Based approach

- ✓ Sinergy with CRANE: Patient's Accessibility is a CRANE Mission keyword

GETTING PREPARED FOR JANE 2 start



Survey

- Part 1: Snapshot of Techniques and Technology Available in your Center**
- Part 2: A snapshot of radiation oncologist's perspectives on RT innovation**
- Part 3: A snapshot of Cost and reimbursement policy**

Part 1: Snapshot of Techniques and Technology Available in your Center

Does your radiotherapy facility have? (check all that apply):

Photon beam radiotherapy

Ablation photon beam radiotherapy (SBRT, radiosurgery) MRI-Linac technology

High dose rate brachytherapy

Pulsed dose rate brachytherapy

Low dose rate brachytherapy

Proton therapy

Proton arc therapy

Proton minibeam

FLASH RT technology

Carbon ion radiotherapy

Boron neutron capture therapy (BNCT)

Nanoparticle-enhance

Upright patient positioning (sitting) solution technology

Other (please specify) _____

Part 2: Radiation Oncologist's perspectives on RT innovation

1. Several RT innovations have been developed in the recent years. For each choice consider the importance on a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements? (Likert scale 1 to 5***)

- MRI- photon beam radiotherapy
- Photon beam Adaptive radiotherapy
- Photon beam 4D CT/MRI planning
- Flash photon beam radiotherapy
- MRI-planning for brachytherapy
- US-planning for brachytherapy
- Implementation of LET analysis for particle beam planning
- Flash particle beam radiotherapy
- 4D CT planning particle beam radiotherapy
- 4D MRI planning particle beam radiotherapy
- Adaptive particle therapy
- 4D particle dose delivering
- Other ions (please specify)_____
- AI auto-contouring tool
- AI auto-planning tool

How would you describe the characteristics of an innovative technique/technology applied to radiation oncology? (check all that apply): *On a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements?* Improvement of therapeutic index (Likert scale 1 to 5*)**

Improvement of clinical work-flow

Reduction of human error

Shorten treatment times

Expansion of treatment options for difficult-to-cure cancer

Use of advanced imaging modalities

Integration of AI

Improvement of tailored-based treatments

Reduction time to achieve specific RT objective (i.e. to finalize the OARs contouring, to finalize plan optimization)

Reduction of healthcare costs

Reduction of toxicities

Impact on disability-adjusted life-years (DALYs)

Improvement of local control

Enhancement of safety and quality of care

Easily accessible worldwide

Approved by regulatory groups

Green Sustainable

Increment of accessibility in clinical trials

Other (please specify) _____

7. How long do you consider an innovation as such? (check all that apply): *On a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements?*

- Until the achievement of clinical evidence
- Until the achievement of maximum enhancement of efficiency or RT delivery
- Until its results are able to change the guidelines and recommendations
- Until the achievement of evidence-based data
- For the time it is included in a trial
- Up to the achievement of global accessibility
- Other (please specify) _____

8. How can AI impact the RT clinical practice? (check all that apply): *On a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements?*

- Replacing the role of RT staff
- Supporting clinical decision
- Reducing workload
- Increasing workload
- I think AI will have no significant impact on clinical practice
- Other (please specify) _____

9.What are the possible barriers that negatively impact the European democratisation access to new technologies? (check all that apply): *On a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements?*

- Lack of clinical evidence
- Highly costs of purchase and maintenance
- Lack of specific reimbursement policy dedicated to the RT departments
- Lack of specific reimbursement policy dedicated to patients to reduce the financial toxicity
- Imbalance in geographical distribution of facilities that allow access to new technology
- Absence of a European cooperative group dedicated to the implementation and integration of new RT technology
- Concerns about privacy and data security (i.e in the use of AI)
- It is more time-consuming compared to conventional technology
- Requiring dedicated staff
- Regulatory issues
- Longer learning curve compared to conventional technologies
- Other (please specify) _____
-

10.How would you describe the accessibility applied to innovation in radiation oncology? (check all that apply): *On a scale from 1 to 5, where 1=strongly disagree and 5=strongly agree, how would you rate the following statements?*

- Strategical geographical location of RT innovation to serve a larger number of patients
- Implementation of telemedicine and mobile RT units to serve also low-income countries or rural areas
- Presence of reimbursement policies
- Ensuring access to high-quality care for all patients
- Lodging accommodation for patients who travel, especially for patients facing financial and logistical challenges
- Physical accessibility to RT departments for patients with disabilities
- Cost-effective value-based radiotherapy
- Other (please specify) _____

Part 3: A snapshot of Cost and Reimbursement Policy

1. Does your country have **official estimates/plans** for future **radiotherapy technological needs**?
2. Is there a difference in reimbursement between treatments consisting of **one or a few fractions** (<5 fractions) and more highly fractionated (> 5 fractions) treatments?
3. Do you have official recommendations/guidelines for the **number of linear accelerators** in the country?
4. Do you have official recommendations/guidelines for the **number of particle beam facilities** in the country?
5. Do you have official recommendations/guidelines for the number of other forms of **innovative radiotherapy** in the country?
6. Is there a special reimbursement for the technology used for **organ motion** management treatments?
7. Is there a special reimbursement for the technology used for **highly hypofractionated treatments** (SBRT or radiosurgery vs conventional treatments)?
8. Is there a special reimbursement for the energy used for treatment (**photons vs particle beam RT**)?
9. Is there a special reimbursement for **AI technology** used in RT treatment or planning?

Criteria for network endorsement (1/2)

Cancer types:

1. frequent cancers
2. rare cancers
3. pediatric cancers

Field of application :

1. - standard of care
2. - clinical research
3. - translational, basic research
4. - public health...

Connection with clinical cooperative groups, CT:

1. - Connected with cooperative groups,
2. - Clinical Trials,
3. - European networks/consortia participation

Human resources, expertise:

1. On-site/network with radiation oncologist, bio-IT, pathologist, medical oncologist, hematologist, surgeons, medical Physicist, Bio-ing, accelerator physicist, Clinical research support professionals, TTO
2. On-site/network with genetist, hemato-onco pediatrician, social-economist expert
3. Continuous professional development

Available infrastructure / core facilities (equipment, TPS, AI, ...):

- Minimal equipment/software: State of the Art linacs; CT scanners dedicated to treatment planning; State-of-the-Art treatment planning system (TPS), State-of-the-Art Record and Verify System (RVS); three-dimensional RT; IMRT techniques (including VMAT, tomotherapy) ; State-of-the-Art Image guided radiotherapy (IGRT)

-Brachithery: High dose rate brachytherapy; Pulsed dose rate brachytherapy; Low dose rate brachytherapy

-Advanced equipment platform/software: stereotactic radiotherapy (SRT); Adaptive Radiotherapy (ART); atlas -based contouring; AI-based contouring; MRI scanners dedicated to treatment planning; PET/CT scanners dedicated to treatment planning; US dedicated to treatment planning

-Continuous technological development: beam qualities and techniques other than photons-based ones both in clinical setting and clinical research, including protons (carbon ion, helium, boron neutron capture therapy, BNCT, FLASH therapy, Proton arc therapy.); TPS with integrated biological function and /or LET optimization and/or AI-based planning

Criteria for network endorsement (2/2)

Clinical Practice guidelines, Training, Education:

1. Twinning program PHD
2. Involvement in setting up international CPG, in (inter)national teaching program (for scientists, technicians, bio-IT...)
3. Involvement / Organisation of seminars, practical courses

Track record:

1. Number of publications/yr including open access (peer-review journal)
2. Number of interdisciplinary publications
3. Patent application
4. Medical device development

In summary:

The EU network on rare cancer (EURACAN) is a reality and opened the way for an innovative approach to health care.

On the same path EU launched 2 JAs to support networking construction.

Within the oncological NOE network construction, high tech innovative RT has the opportunity to conceptualise drive, shape and develop the way in which innovative RT will be implemented in the EU oncological community.